Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 220 clinical trials
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 …

contraceptive use
chronic progressive multiple sclerosis
disease or disorder
secondary progressive multiple sclerosis
Investigational Site Number 7240001
 (3.7 away) Contact site
  • 128 views
  • 23 Jul, 2021
  • +223 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

cancer chemotherapy
targeted therapy
measurable disease
stage iv non-small cell lung cancer
pemetrexed
Hospital Universitario Quiron Madrid ( Site 1200)
 (3.7 away) Contact site
  • 51 views
  • 26 Sep, 2021
  • +191 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

cardiovascular disease
body mass index
hemoglobin a1c
Hospital Universitario Quironsalud Madrid
 (3.7 away) Contact site
  • 597 views
  • 26 Sep, 2021
  • +896 other locations
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

malignant melanoma of skin
complete resection
immunologic adjuvant
melanoma skin
metastasis
Investigator Site
 (8.2 away) Contact site
  • 0 views
  • 16 Sep, 2021
  • +247 other locations
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Patients will be randomly assigned to …

measurable disease
lenalidomide
avid
rituximab
b-cell lymphoma
Hospital Universitario Quironsalud Madrid
 (3.7 away) Contact site
  • 0 views
  • 27 Sep, 2021
  • +80 other locations
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.

refractory multiple myeloma
measurable disease
lenalidomide
proteasome inhibitor
dexamethasone
Hospital Fundacion Jimenez Dia /ID# 171304
 (8.2 away) Contact site
  • 91 views
  • 28 Sep, 2021
  • +268 other locations
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

lasmiditan
migraine in children
acute treatment
ly573144
Hospital Universitario Quironsalud Madrid
 (3.7 away) Contact site
  • 139 views
  • 28 Sep, 2021
  • +243 other locations
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

cancer chemotherapy
measurable disease
BRAF
docetaxel
proto-oncogene tyrosine-protein kinase ros
Hospital Puerte de Hierro de Majadahonda
 (4.7 away) Contact site
  • 0 views
  • 17 Sep, 2021
  • +196 other locations
Study to Evaluate the Safety Tolerability and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 g of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 700 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants …

Hospital Universitario HM Monteprincipe
 (0.9 away) Contact site
  • 18 views
  • 23 Sep, 2021
  • +137 other locations
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea ) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group or aflibercept (Treatment …

Hospital Cl nico San Carlos
 (9.7 away) Contact site
  • 57 views
  • 28 Sep, 2021
  • +225 other locations